Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572764 · ClinicalTrials.gov registry record · Phase 1
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Phase 1 study of Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT03572764: Active Phase 1 study of Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
NCT03572764 is a Phase 1 study of Myelodysplastic Syndromes that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03572764, a Phase 1 study of Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.
Conditions Studied
Interventions
- DRUG CPX-351
- PROCEDURE Research blood draw
- PROCEDURE Research skin biopsy
- PROCEDURE Research bone marrow aspirate
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
Missouri
- Washington University School of Medicine - St Louis
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2027-03-25 |
| Phase | Phase 1 |
What the registry record for NCT03572764 still lists
NCT03572764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 4 interventions - of which CPX-351 is the first listed.
NCT03572764 reports a single indexed study location in Florida, Missouri, Washington.
Frequently Asked Questions
What is clinical trial NCT03572764 about?
NCT03572764 is a clinical study titled "CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome". This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients pr...
What is the current status of trial NCT03572764?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-12-14. Estimated completion is 2027-03-25.
What conditions does trial NCT03572764 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03572764?
The interventions under investigation include: CPX-351 (DRUG), Research blood draw (PROCEDURE), Research skin biopsy (PROCEDURE), Research bone marrow aspirate (PROCEDURE).
Who is sponsoring clinical trial NCT03572764?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03572764 being conducted?
This trial has 3 study locations across Florida, Missouri, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03572764's enrollment target sits among peer trials
20 140th of 173 higher than 30 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI